TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00326027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Efficacy of Pantoprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Efficacy of Pantoprazole
Study: NCT03045692

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: kidney function assessment by 4 hour creatinine clearance
Description: 4 hour creatinine clearance is used to decide colistin maintenance dosage.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: kidney function assessment by creatinine based eGFR
Description: creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
Study: NCT00926393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine Immediate Release
Description: Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine Extended Release
Description: Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
Study: NCT01749787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 1.5 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 3.0 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 6.0 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 12.0 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 240 mcg
Study: NCT01884064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS
Study: NCT01854658

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02339285

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS (alpha)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS (alpha)
Study: NCT03746431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [111In]-FPI-1547 Injection
Description: \[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [111In]-FPI-1547 Injection
Description: \[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [225Ac]-FPI-1434 Injection multi-dose
Description: \[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of \[225Ac\]-FPI-1434 Injection. Dose is per cohort assignment.
Study: NCT02339285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS (gamma)
Study: NCT03832777

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Subjects will receive both active and placebo rTMS, in a crossover modality.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Subjects will receive both active and placebo rTMS, in a crossover modality.
Study: NCT03746431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [225Ac]-FPI-1434 Injection multi-dose
Description: \[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of \[225Ac\]-FPI-1434 Injection. Dose is per cohort assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [225Ac]-FPI-1434 Injection multi-dose
Description: \[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of \[225Ac\]-FPI-1434 Injection. Dose is per cohort assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPI-1175 Infusion
Description: FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPI-1175 Infusion
Description: FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPI-1175 Infusion
Description: FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [225Ac]-FPI-1434 Injection single-dose
Description: \[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of \[225\]-FPI-1434 Injection. Dose is per cohort assignment.
Study: NCT00515229

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: amitriptyline
Description: Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch
Study: NCT04031508

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: lipid injectable emulsion with Fish oil
Description: TPN will start at 1.5-2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 3.0 g/kg/d for at least 7 days.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: lipid injectable emulsion with Fish oil
Description: TPN will start at 1.5-2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 3.0 g/kg/d for at least 7 days.
Study: NCT03140969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-110
Description: RNA antisense oligonucleotide for intravitreal injection
Study: NCT01969058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
Study: NCT02708901

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx®
Description: Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx®
Description: Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
Study: NCT03878238

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Bths-003
Description: Probiotic with maltodextrin as a carrier.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with maltodextrin base.
Study: NCT02322073

Intervention type: PROCEDURE
Intervention: Laparoscopic surgery
Description: Roux-en-Y gastric bypass or other benign laparoscopic surgery
Study: NCT02834728

Intervention type: BEHAVIORAL
Intervention: telephone interview
Study: NCT03835871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention: Drug: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention: Drug: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention: Drug: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 µg per day Beclomethasone
Description: Intervention: Drug: Beclomethasone 400 µg HFA per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 µg per day Beclomethasone
Description: Intervention: Drug: Beclomethasone 200 µg HFA per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 µg per day Beclomethasone
Description: Intervention: Drug: Beclomethasone 100 µg HFA per day
Study: NCT05890144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Big Canoe
Description: The Big Canoe will involve an intensive, multi-modular Indigenous cultural safety education training program that is offered online and led by trained facilitators. It is 10 modules long and takes 10 weeks to complete (1 hour of learning per week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Little Canoe
Description: The Little Canoe involves a brief, 2-hour, interactive, computer-based Indigenous race-bias education session that is offered in a computer lab with a researcher present and followed up with 2 reinforcement/reminder emails that ask questions about strategy usage at 6 and 8 weeks after the session

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control is a primary care-related training program that is time-attention matched to Arm 1 but does not contain any content on anti-bias, anti-oppression, Indigenous peoples, or any content related to the unannounced Indigenous standardized patient encounter.
Study: NCT02138773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin formulation-A
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin formulation-A
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin formulation-B
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin formulation-B
Description: oral
Study: NCT03939026

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ALLO-501
Description: ALLO-501 is an allogeneic CAR T cell therapy targeting CD19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-647
Description: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion
Study: NCT04389216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cool-tip electrode for Radiofrequency Ablation
Description: Radiofrequency ablation of the tumour in the surgery group, associated whith axillary surgery when applicable
Study: NCT02360995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/fluoride toothpaste
Description: Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stannous fluoride toothpaste
Description: Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluoride toothpaste
Description: Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride Mouthwash
Description: Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetylpyridinium chloride Mouthwash
Description: Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
Study: NCT02796703

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Heat Inactivated probiotics
Description: Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 cc of milk will be given to control group
Study: NCT04703387

Intervention type: DIAGNOSTIC_TEST
Intervention: transthoracic echocardiography
Description: Trans-mitral flow velocities (peak early diastolic E and peak late diastolic A) will be recorded with pulsed-wave Doppler, placing the sample volume at the mitral valve tips from the apical 4-chamber view; deceleration time of the E wave (DTE) will be measured. Peak early diastolic velocity will be obtained with tissue Doppler imaging (TDI), in the apical 4-chamber view, positioning the pulsed-wave Doppler sample volume at or 1 cm within the septal insertion sites of the mitral leaflets, so as to cover the longitudinal excursion of the mitral annulus in both systole and diastole. Then, the E/A ratio and the trans-mitral inflow E wave to mitral annular e' (E/e) will be calculated.Diaphragmatic thickness will be assessed in the zone of apposition of the diaphragm to the rib cage between the 8th and 10th intercostal spaces using a 3-12 MHz linear array probe , we will record changes in diaphragm vertical excursion using M-mode ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: transthoracic echocardiography
Description: Trans-mitral flow velocities (peak early diastolic E and peak late diastolic A) will be recorded with pulsed-wave Doppler, placing the sample volume at the mitral valve tips from the apical 4-chamber view; deceleration time of the E wave (DTE) will be measured. Peak early diastolic velocity will be obtained with tissue Doppler imaging (TDI), in the apical 4-chamber view, positioning the pulsed-wave Doppler sample volume at or 1 cm within the septal insertion sites of the mitral leaflets, so as to cover the longitudinal excursion of the mitral annulus in both systole and diastole. Then, the E/A ratio and the trans-mitral inflow E wave to mitral annular e' (E/e) will be calculated.Diaphragmatic thickness will be assessed in the zone of apposition of the diaphragm to the rib cage between the 8th and 10th intercostal spaces using a 3-12 MHz linear array probe , we will record changes in diaphragm vertical excursion using M-mode ultrasound.
Study: NCT01081288

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation for breast screening
Description: Invitation for breast screening to women in different age groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation for breast screening
Description: Invitation for breast screening to women in different age groups
Study: NCT00820352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bosentan
Description: 4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo twice a day for 12 weeks
Study: NCT03302650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will receive normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: patients will receive norepinephrine infusion adjusted according to blood pressure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norepinephrine
Description: patients will receive norepinephrine infusion adjusted according to blood pressure
Study: NCT02431338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Intermittent arm ischemia through four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff placed around the upper arm.
Study: NCT03110926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Induction Chemotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Chemoradiation
Study: NCT01381484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Argireline
Description: 10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
Study: NCT04673968

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prehabilitation
Description: inhospital exercise training 5 times/week, 5\~6 weeks during nCRT; home exercise 5 times/week, 5\~6 weeks, between completion of nCRT and before surgery
Study: NCT03039452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Each training session will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
Study: NCT03267836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: -10mg/kg IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Description: -Proton therapy will start concurrently with the first dose of avelumab (up to 3 days before or after is permissible) and will be administered once daily during weekdays (Monday through Friday).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: -Standard of care
Study: NCT00935948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imescard compound water smartweed ointment
Description: Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
Study: NCT02031796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAVAREC Image Processing algorithm
Description: After deployment of the TAVI prosthesis, other trans catheter valve, or stent, but before the patient care episode is completed, a set of rotational x-ray angiography images will be acquired and reconstructed using the clinical DyanCT and research CAVAREC algorithms.
Study: NCT03386318

Intervention type: DRUG
Intervention: Oxycodone
Description: Serum concentration per hour from 1 to 5 h
Study: NCT01629992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative counseling
Description: The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
Study: NCT04195906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: SNF472
Description: Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimatenl SNF472 (Open-label)
Description: Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
Study: NCT02299882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Patient will be randomized to either vancomycin or no vancomycin. This treatment will take place prior to the closure of the incision from back surgery.
Study: NCT00928395

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgent PC
Description: The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
Study: NCT02008318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT03460275

Intervention type: DRUG
Group type: OTHER
Intervention: Osimertinib Mesylate Tablets
Description: Osimertinib 80mg oral administration daily until progression or occurring intolerable treatment-related toxic effects or patients withdrawing informed consent(Based on whichever occurs first)